You are here:

fentanyl sublingual (Abstral)

Advice

Following an abbreviated submission

fentanyl sublingual tablets (Abstral) are accepted for restricted use in NHS Scotland for the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain.

Use of sublingual fentanyl tablets should be restricted to patients who are unsuitable for other short-acting opioids e.g. oral morphine. This product offers an alternative to buccal administration at a reduced cost per administration.

Prescribers should be aware of the differing absorption and elimination characteristics of available oral fentanyl preparations; doses are not interchangeable.

Drug Details

Drug Name: fentanyl sublingual (Abstral)
SMC Drug ID: 534/09
Manufacturer: ProStrakan
Indication: Management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain
BNF Category:
Sub Category: 4.7 Analgesics
Submission Type: Abbreviated Submission
Status: Restricted
Date Advice Published: 9 February 2009

Back